Healthcare behemoth Johnson & Johnson (JNJ +1.48%) pays a very healthy dividend. It offered a dividend yield of more than 2% in mid-2026, more than double the S&P 500's level. Meanwhile, it has 64 consecutive years of dividend increases, following a 3.1% increase in April 2026.
The healthcare company is a financial fortress. It had an elite AAA bond rating (higher than the U.S. government). Johnson & Johnson ended the first quarter of 2026 with $22.1 billion in cash and $55 billion in debt. Meanwhile, it generated $20 billion in free cash flow in 2025 (more than enough to cover its $12.4 billion dividend payout).
Johnson & Johnson expects to grow its operational sales at a 5%-7% annual rate through 2030, driven in part by a target to grow oncology sales to $50 billion by that year. Meanwhile, its strong balance sheet will give it the flexibility to make acquisitions to further boost its growth (it agreed to acquire Firefly Bio for $1 billion in June 2026 to expand its oncology platform). These factors put it in a strong position to continue increasing its dividend.